EE200200529A - Tsüklilised ß-aminohappe derivaadid kui maatriksmetalloproteaaside ja TNF-a inhibiitorid - Google Patents

Tsüklilised ß-aminohappe derivaadid kui maatriksmetalloproteaaside ja TNF-a inhibiitorid

Info

Publication number
EE200200529A
EE200200529A EEP200200529A EEP200200529A EE200200529A EE 200200529 A EE200200529 A EE 200200529A EE P200200529 A EEP200200529 A EE P200200529A EE P200200529 A EEP200200529 A EE P200200529A EE 200200529 A EE200200529 A EE 200200529A
Authority
EE
Estonia
Prior art keywords
tnf
inhibitors
cyclic
amino acid
acid derivatives
Prior art date
Application number
EEP200200529A
Other languages
English (en)
Inventor
Duan Jingwu
Chen Linhua
R. Ott Gregory
Decicco Carl
Lu Zhonghui
P. Maduskuie Thomas Jr.
E. Voss Matthew
Xue Chu-Biao
Original Assignee
Bristol-Myers Squibb Pharma Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Pharma Company filed Critical Bristol-Myers Squibb Pharma Company
Publication of EE200200529A publication Critical patent/EE200200529A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/08—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
EEP200200529A 2000-03-17 2001-03-15 Tsüklilised ß-aminohappe derivaadid kui maatriksmetalloproteaaside ja TNF-a inhibiitorid EE200200529A (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19018200P 2000-03-17 2000-03-17
US23337300P 2000-09-18 2000-09-18
US25553900P 2000-12-14 2000-12-14
PCT/US2001/008334 WO2001070673A2 (en) 2000-03-17 2001-03-15 CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a)

Publications (1)

Publication Number Publication Date
EE200200529A true EE200200529A (et) 2004-02-16

Family

ID=27392700

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200529A EE200200529A (et) 2000-03-17 2001-03-15 Tsüklilised ß-aminohappe derivaadid kui maatriksmetalloproteaaside ja TNF-a inhibiitorid

Country Status (20)

Country Link
US (2) US6743807B2 (et)
EP (1) EP1263755A2 (et)
JP (1) JP2003528072A (et)
KR (1) KR20030009391A (et)
CN (1) CN1481377A (et)
AR (1) AR035710A1 (et)
AU (1) AU2001250849A1 (et)
BR (1) BR0109467A (et)
CA (1) CA2401870A1 (et)
CZ (1) CZ20023033A3 (et)
EE (1) EE200200529A (et)
HK (1) HK1049165A1 (et)
HU (1) HUP0300850A2 (et)
IL (1) IL151552A0 (et)
MX (1) MXPA02009020A (et)
NO (1) NO20024402D0 (et)
NZ (1) NZ521248A (et)
PL (1) PL360678A1 (et)
SK (1) SK13072002A3 (et)
WO (1) WO2001070673A2 (et)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60037345T2 (de) 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
US6720329B2 (en) * 2001-03-15 2004-04-13 Bristol-Myers Squibb Pharma Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE)
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1427408A4 (en) 2001-09-17 2005-10-26 Bristol Myers Squibb Co CYCLIC HYDROXAMINE ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-a-CONVERTASE (TACE TNF-a-CONVERTING ENZYM)
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
AR040336A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
AU2003263393A1 (en) * 2002-09-04 2004-03-29 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
US6835841B2 (en) 2002-09-13 2004-12-28 Bristol-Myers Squibb Company Asymmetric catalytic hydrogenation process for preparation of chiral cyclic β-aminoesters
AP2021A (en) 2002-10-23 2009-08-03 Glenmark Pharmaceuticals Ltd Novel tricyclic compounds useful for the treatmentof inflammatory and allergic disorders: Process f or their preparation and pharmaceutical compositions containing them
CN101353321A (zh) * 2002-11-21 2009-01-28 辉瑞产品公司 3-氨基-哌啶衍生物及其制备方法
GEP20084526B (en) 2003-04-11 2008-11-10 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders, process for their preparation and pharmaceutical compositions containing them
HRP20160180T1 (hr) 2003-04-24 2016-03-25 Incyte Holdings Corp Derivati aza spiro alkana kao inhibitori metaloproteaza
US7326790B2 (en) * 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
JP2007525482A (ja) 2003-10-07 2007-09-06 レノビス， インコーポレイテッド イオンチャネルリガンドとしてのアミド化合物およびその使用
GB2413129A (en) * 2003-10-07 2005-10-19 Renovis Inc Aromatic amide compounds as ion channel ligands and uses thereof
WO2005037826A1 (en) 2003-10-17 2005-04-28 Incyte Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
ES2562778T3 (es) * 2003-12-02 2016-03-08 The Ohio State University Research Foundation Ácidos grasos de cadena corta unidos a motivos quelantes de Zn2+ como una clase novedosa de inhibidores de histona deacetilasa
EP1711495A2 (en) 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
CA2553423C (en) 2004-01-23 2012-03-20 Amgen Inc. Heterocyclic compounds for use in the treatment of cancer and the inhibition of angiogenesis
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
CN102558082B (zh) 2004-03-05 2015-09-30 日产化学工业株式会社 异噁唑啉取代苯甲酰胺化合物的制备中间体
US7683097B2 (en) * 2004-05-27 2010-03-23 Propharmacon Inc. Topoisomerase inhibitors
EP1768954A4 (en) 2004-06-24 2008-05-28 Incyte Corp 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS
JP2009519206A (ja) 2004-10-13 2009-05-14 グレンマーク・ファーマシューティカルズ・エスエー Ｎ−（３，５−ジクロロピリジン−４−イル）−４−ジフルオロメトキシ−８−メタンスルホンアミド−ジベンゾ［ｂ，ｄ］フラン−１−カルボキサミドの製造法
MX2007006230A (es) 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
MX2007006790A (es) * 2004-12-07 2007-08-15 Toyama Chemical Co Ltd Novedosos derivado de acido antranilico o sal del mismo.
UA88795C2 (ru) 2004-12-17 2009-11-25 Гленмарк Фармасьютікалс С.А. Гетероциклические соединения, которые применяются для лечения воспалителных и аллергических нарушений
AP2334A (en) 2004-12-17 2011-12-06 Glenmark Pharmaceuticals Sa Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders.
US7595327B2 (en) 2005-03-21 2009-09-29 Wyeth Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase
GB0505969D0 (en) 2005-03-23 2005-04-27 Novartis Ag Organic compounds
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2006123762A1 (ja) * 2005-05-16 2006-11-23 Sumitomo Chemical Company, Limited ピロリジン化合物の製造方法
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
CN101351442B (zh) * 2005-10-27 2011-12-14 住友化学株式会社 酰胺化合物及其用途
WO2007053498A1 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
US20100016289A1 (en) * 2005-11-01 2010-01-21 Kevin Sprott Compounds Useful as Antagonists of CCR2
US8067415B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
PT2420491E (pt) 2005-12-30 2013-10-14 Novartis Ag Compostos de piperidina 3,5-substituída como inibidores de renina
WO2008070161A1 (en) * 2006-12-06 2008-06-12 The Research Foundation Of State University Of New York Azepans and methods for making and using same
EP2151437A4 (en) 2007-03-07 2012-05-02 Nissan Chemical Ind Ltd ISOXAZOLINE SUBSTITUTED BENZAMIDE COMPOUND AND PEST CONTROL AGENT
CA2689109A1 (en) 2007-06-25 2008-12-31 Novartis Ag N5-(2-ethoxyethyl)-n3-(2-pyridinyl) -3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
US8278313B2 (en) 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
TW201010997A (en) 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
US20120115907A1 (en) * 2009-04-24 2012-05-10 Cadila Healthcare Limited Novel compounds as inhibitors of renin
NZ598985A (en) 2009-09-04 2013-07-26 Biogen Idec Inc Bruton's tyrosine kinase inhibitors
WO2011140190A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Tetrazolones as inhibitors of fatty acid synthase
WO2012060884A1 (en) * 2010-11-04 2012-05-10 Nestec S.A. Methods and compositions for preventing and treating osteoarthritis
WO2012079154A1 (en) * 2010-12-14 2012-06-21 Dalhousie University Selective estrogen receptor modulators
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
EP2684865A1 (en) * 2012-07-13 2014-01-15 Heidelberg Pharma GmbH Methods for synthesizing amatoxin building block and amatoxins
EP3057964B1 (en) 2013-10-14 2019-12-04 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
JP6483666B2 (ja) 2013-10-14 2019-03-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的に置換されたキノリン化合物
US10112939B2 (en) 2014-08-21 2018-10-30 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
JP7214632B2 (ja) 2016-07-21 2023-01-30 バイオジェン エムエー インク． ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
WO2020070239A1 (en) 2018-10-04 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
KR102614653B1 (ko) * 2021-06-09 2023-12-20 한국과학기술연구원 신규한 헤테로사이클릴-페닐-메틸아민 유도체, 이의 제조방법 및 이의 다발성 경화증 예방, 개선, 또는 치료 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212182A (en) * 1990-10-03 1993-05-18 American Home Products Corpooration Substituted quinolinyl- and naphthalenylbenzamides or benzylamines and related compounds useful as analgesics
DE69626684T2 (de) 1995-12-08 2004-04-29 Agouron Pharmaceuticals, Inc., La Jolla Metallproteinasehemmer, diesen enthaltende pharmazeutische zusammensetzung und dessen pharmazeutische verwendung und verfahren zu ihrer herstellung
PT780386E (pt) 1995-12-20 2003-02-28 Hoffmann La Roche Inibidores de metaloprotease de matriz
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
CA2263928A1 (en) * 1996-08-28 1998-03-05 Michael George Natchus Substituted cyclic amine metalloprotease inhibitors
US6420427B1 (en) * 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
AU3669700A (en) * 1999-04-06 2000-10-23 Ono Pharmaceutical Co. Ltd. 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
AUPP982399A0 (en) 1999-04-19 1999-05-13 Fujisawa Pharmaceutical Co., Ltd. Mmp inhibitor
AU4249700A (en) * 1999-04-19 2000-11-02 Sumitomo Pharmaceuticals Company, Limited Hydroxamic acid derivative

Also Published As

Publication number Publication date
US20040162426A1 (en) 2004-08-19
NZ521248A (en) 2004-04-30
WO2001070673A3 (en) 2002-03-14
CN1481377A (zh) 2004-03-10
AU2001250849A1 (en) 2001-10-03
EP1263755A2 (en) 2002-12-11
US6743807B2 (en) 2004-06-01
WO2001070673A2 (en) 2001-09-27
SK13072002A3 (sk) 2003-08-05
HK1049165A1 (zh) 2003-05-02
CA2401870A1 (en) 2001-09-27
KR20030009391A (ko) 2003-01-29
PL360678A1 (en) 2004-09-20
US20020016336A1 (en) 2002-02-07
MXPA02009020A (es) 2003-02-12
IL151552A0 (en) 2003-04-10
CZ20023033A3 (cs) 2003-01-15
NO20024402D0 (no) 2002-09-13
US6984648B2 (en) 2006-01-10
JP2003528072A (ja) 2003-09-24
HUP0300850A2 (hu) 2003-07-28
AR035710A1 (es) 2004-07-07
BR0109467A (pt) 2003-06-03

Similar Documents

Publication Publication Date Title
EE200200529A (et) Tsüklilised ß-aminohappe derivaadid kui maatriksmetalloproteaaside ja TNF-a inhibiitorid
IL151018A0 (en) Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
NO20023319D0 (no) Substituerte glutarimider og deres anvendelse som inhibitorer av IL-12-produksjonen
IS6828A (is) Nýjar afleiður möndlusýru og notkun þeirra sem þrombínhemla
EE200200328A (et) Multši kompositsioon ja meetod
ATE245032T1 (de) Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen
FR2812875B1 (fr) Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
NO20025079D0 (no) Inhibitorer av dipeptidylpeptidase IV
DE60121953D1 (de) Herstellungsverfahren von arzneizubereitungen
IS6254A (is) Lyfjasamsetningar sem innihalda HMG afoxunarensímlata
EE200300459A (et) Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
DE60028552D1 (de) Verwendung von dipeptidyl peptidase IV Inhibitoren zur Verbesserung der Fruchtbarkeit
NO20013844L (no) Forgrenet kjede-aminosyreavhengige aminotransferase inhibitorer og deres anvendelse av diabetisk retinopati
EE03745B1 (et) Asendatud 4-bifenüül-4-hüdroksübutaanhappe derivaadid metalloproteaasimaatriksi inhibiitoritena
EE200200462A (et) Piperidiini ja piperasiiniga asendatud N-hüdroksüformamiidid kui metalloproteinaaside inhibiitorid
EE200100611A (et) NOS inhibiitorite uued farmatseutilised kombinatsioonid
AU2001265182A1 (en) Inhibitors of matrix metalloproteinases
DE50115086D1 (de) Lösungen von UV-vernetzbaren Polyacrylaten
DE60117938D1 (de) Vorspannen von Bauteilen
DK1047665T3 (da) Matrix metalloprotease inhibitorer
ITMI20021074A0 (it) Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione
FI20000411L (fi) Menetelmä elektrodin valmistamiseksi ja elektrodi
ATE228122T1 (de) Umgekehrt hydroxamat inhibitoren von matrix metalloproteinasen
ATE323673T1 (de) Pyrrolidin-2-carbonsäure-hydrazid-derivate als metalloprotease-inhibitoren